Infinimmune Raises $12 Million In Seed Funding To Pioneer Novel Approach To Antibody Drug Discovery And Development

Dec 06, 2022•about 3 years ago

Amount Raised

$12 Million

Round Type

seed

AlamedaTherapeuticsBiotechnologyHealth Care

Investors

Axial VcCivilization VenturesPear Vc

Description

Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, today announced that it has closed a $12 million seed round led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier.

Company Information

Company

Infinimmune

Location

Alameda, California, United States

About

Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications.

Related People

1 contact

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends